A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions.

Xia LiSebastian FrechenDaniel MojThorsten LehrMax TaubertChih-Hsuan HsinGerd MikusPertti J NeuvonenKlaus T OlkkolaTeijo I SaariUwe Fuhr

Published in: Clinical pharmacokinetics (2021)

Both the in vitro assay and model-based simulations support TDI of CYP3A4 by voriconazole as a pivotal characteristic of this drug's PK. The PBPK model developed here could support individual dose adjustment of voriconazole according to genetic polymorphisms of CYP2C19, and DDI risk management. The applicability of modeling results for patients remains to be confirmed in future studies.

Keyphrases

end stage renal disease
chronic kidney disease
peritoneal dialysis
prognostic factors
high throughput
emergency department
patient reported outcomes
drug induced
patient reported
case control
electronic health record